MedTrace Logo

Arrhythmia Detection With MEMO Patch Plus in Patients With Acute Heart Failure

NCT07792772 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-08-28

No results posted yet for this study

Summary

This prospective, multicenter, open-label, single-group exploratory clinical trial evaluates the clinical effectiveness of extended electrocardiographic monitoring with MEMO Patch Plus for detecting clinically significant arrhythmias in adult patients hospitalized with acute heart failure.

Eligible participants receive continuous electrocardiographic monitoring with MEMO Patch Plus for up to 14 days during hospitalization and again for up to 14 days after discharge. Participants return the post-discharge device by mail, review the monitoring results approximately 6 weeks after discharge, and complete a final follow-up assessment approximately 12 weeks after discharge.

The primary outcome is the proportion of participants in whom a clinically significant arrhythmia is detected. Secondary outcomes include the detection of other arrhythmias, changes in clinical management following an arrhythmia diagnosis, major clinical events through 3 months after discharge, atrial fibrillation or atrial flutter burden, the longest atrial fibrillation or atrial flutter episode, and adherence to MEMO Patch Plus monitoring.

Conditions

  • Acute Heart Failure (AHF)
  • Cardiac Arrhythmia

Interventions

DEVICE

MEMO Patch Plus

MEMO Patch Plus is a wearable, noninvasive electrocardiographic monitoring device designed for long-term recording and reproduction of electrocardiographic signals. In this study, eligible participants receive MEMO Patch Plus on Day 1 and wear the device during hospitalization for up to 14 days. At discharge, participants receive another MEMO Patch Plus device and wear it for up to 14 additional days after discharge. The device records electrocardiographic data for the detection of clinically significant and other arrhythmias. Clinically significant arrhythmias include a pause lasting 3 seconds or longer, high-degree or complete atrioventricular block, atrial fibrillation or atrial flutter, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation.

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • Korea University Anam Hospital

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • HUINNO Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-11
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07792772 on ClinicalTrials.gov